Evidence map›Paper›PMID 39682301›Full record

ArticleCancers2024

Pancreatectomy with Celiac Axis Resection and Reconstruction for Locally Advanced Pancreatic Cancer.

Satoshi Mizutani, Nobuhiko Taniai, Makoto Sukegawa, Takahiro Haruna, Hiroyasu Furuki, Hideyuki Takata, Junji Ueda, Masato Yoshioka, Takayuki Aimoto, Shunichiro Sakamoto and 3 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Satoshi MizutaniDigestive Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.ORCID 0000-0002-5599-2321
Nobuhiko TaniaiDigestive Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.
Makoto SukegawaDigestive Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.ORCID 0000-0003-0773-7243
Takahiro HarunaDigestive Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.
Hiroyasu FurukiDigestive Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.
Hideyuki TakataDigestive Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.
Junji UedaDigestive Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.
Masato YoshiokaDigestive Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.
Takayuki AimotoDigestive Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.
Shunichiro SakamotoDepartment of Cardiovascular Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.
Kenji SuzukiDepartment of Cardiovascular Surgery, Nippon Medical School Musashikosugi Hospital, 1-383 Kosugimachi, Nakahara, Kawasaki 211-8533, Kanagawa, Japan.ORCID 0000-0002-2387-6756
Yoshiharu NakamuraDepartment of Surgery, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamakari, Inzai 270-1694, Chiba, Japan.ORCID 0000-0002-9504-5337
Hiroshi YoshidaDepartment of Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo, Tokyo 113-8603, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the advent of effective chemotherapy, conversion surgery (CS) has been performed in patients who have responded to pretreatment, even for pancreatic cancer diagnosed as unresectable (UR) at the time of initial diagnosis. In CS, major arterial resection and reconstruction are necessary for complete radical resection.

methodsWe discuss the key points for safely performing pancreatectomy with celiac axis (CA) resection combined with reconstruction, divided into resection and arterial reconstruction. The possibility of safe pancreatectomy concurrent with CA resection and reconstruction depends on the ability to create a "golden view" that provides an unimpaired view of the Abdominal Aorta, CA, Superior Mesenteric Artery, Inferior Vena Cava, and left renal vein from the ventral side. Pancreatectomy concurrent with CA resection requires arterial reconstruction. Postoperatively, arterial blood flow must be maintained. To achieve this, tension-free and short bypass should be observed.

resultsFrom 2014 to 2024, sixteen URLA patients underwent CS, requiring major artery en bloc resection after pretreatment. We performed DP-CAR in eight patients, gastrectomy-distal pancreatectomy-splenectomy (Appleby procedure) procedure in one patient, PD-CHAR in two patients, PD-CAR in two patients, TP-CAR(spleen preserving) in one patient, and TP-CAR+TG in two patients. In total, five patients required surgery with CA reconstruction. Histopathologically, four of the five patients had T4 pancreatic cancer. The R0 surgical rate was 80%. Complication of Clavien-Dindo IIIa or higher was observed in one patient. There were no deaths.

conclusionsParallel to the determination of pretreatment, surgeons must be prepared to safely and reliably perform pancreatectomies that require concurrent major arterial resection and reconstruction.

Indexed as

extended pancreatectomypancreatic ductal adenocarcinoma (PDAC)vascular resection and reconstruction

Identifiers

PMID39682301
PMCPMC11639852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.